ATACS

(1) A trial that compared aspirin + anticoagulation vs aspirin alone, when added to conventional antianginal therapy, in cardiac mortality and morbidity in nonprior aspirin users with unstable rest angina or non-Q-wave infarction.
Conclusion Combination anticoagulation plus aspirin reduces recurrent ischemia in high-risk patients with a slight increased risk of bleeding.
(2) A trial comparing 2 formulations of aspirin in preventing recurrent angina.
Conclusion Prostacyclin-sparing controlled release is no better than conventional aspirin.

Mentioned in

References in periodicals archive

Heidelberg Pharma developed the toxin Amanitin into cancer therapies using its proprietary ATAC technology and advanced the biological mode of action of the toxin as a novel therapeutic principle.

Magenta Therapeutics and Heidelberg Pharma Partner to Develop Antibody Drug Conjugates

Accordingly, ATACs exhibit comparable activity against proliferating and resting tumour cells.

Wilex's unit extends agreement with Roche over ADCs development

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.